Regulatory T cell therapy in autoimmune and immune-mediated diseases: from basic research to clinical practice and future perspectives
Frontiers in Immunology · 07.05.2026 · 17
DOI: 10.3389/fimmu.2026.1772001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 07.05.2026. Verfasst von Shihao Duan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University, Chongqing, China. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Autoimmune Diseases, Immune System Diseases, Immunotherapy, Adoptive. Die Arbeit nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Regulatory T cells (Tregs) are pivotal immune modulators essential for maintaining immune homeostasis and preventing aberrant immune responses. In recent years, Treg-based therapies have emerged as a promising strategy for treating a variety of non-malignant diseases, including autoimmune disorders, transplantation-related complications, and allergic conditions. This review provides a comprehensive overview of the discovery and evolution of Tregs, detailing their immunoregulatory mechanisms that underpin their therapeutic potential. We systematically evaluate current clinical applications of Treg therapy in diverse non-tumor pathologies, highlighting both the efficacy and safety outcomes reported in ongoing clinical trials. Additionally, the review addresses the challenges faced in translating Treg therapies from bench to bedside, such as cell stability, expansion methodologies, and functional heterogeneity. Finally, we explore future directions in Treg research, including innovative therapeutic approaches, advances in gene engineering technologies, and improvements in cell expansion techniques, all aimed at enhancing the clinical translation and therapeutic efficacy of Treg-based interventions. This article aims to provide a thorough theoretical foundation and practical guidance to advance the application of Treg therapy in non-malignant diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University, Chongqing, China.
- Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China.
Zitieren
APA
Duan, S., Zhang, J., Chen, Z., He, Y., Zhang, Y., & Guo, H. (2026). Regulatory T cell therapy in autoimmune and immune-mediated diseases: from basic research to clinical practice and future perspectives. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1772001
Vancouver
Duan S, Zhang J, Chen Z, He Y, Zhang Y, Guo H. Regulatory T cell therapy in autoimmune and immune-mediated diseases: from basic research to clinical practice and future perspectives. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1772001
BibTeX
@article{Duan2026,
author = {Duan, Shihao and Zhang, Junyan and Chen, Zhongxiu and He, Yong and Zhang, Yingzhi and Guo, Hong},
title = {Regulatory T cell therapy in autoimmune and immune-mediated diseases: from basic research to clinical practice and future perspectives},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1772001}
}
EUVIMED